Literature DB >> 2569792

Changing patterns of psychotropic drug use in the elderly: a five-year update.

R B Stewart1, F E May, M T Moore, W E Hale.   

Abstract

Psychotropic drug use was evaluated in 2022 ambulatory elderly subjects in 1978-80 and again in 1984-86. Use of hypnotic drugs declined from 8.5 percent (n = 3234) in 1978-80 to 6.3 percent (n = 2681) in 1984-86 (p less than 0.01). Use of the long-acting hypnotic flurazepam decreased (p less than 0.01) and use of two short-acting drugs, triazolam and temazepam, increased. Prescribing of long half-life benzodiazepines, such as diazepam (p less than 0.01) and chlordiazepoxide, clorazepate, halazepam, and prazepam as a group (p less than 0.01) decreased as well as the use of nearly all products containing barbiturates (p less than 0.01).

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2569792     DOI: 10.1177/1060028089023007-821

Source DB:  PubMed          Journal:  DICP        ISSN: 1042-9611


  5 in total

Review 1.  Administrative initiatives for reducing inappropriate prescribing of psychotropic drugs in nursing homes: how successful have they been?

Authors:  Carmel M Hughes; Kate L Lapane
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

Review 2.  Pharmacy interventions on prescribing in nursing homes: from evidence to practice.

Authors:  Carmel M Hughes; Kate L Lapane
Journal:  Ther Adv Drug Saf       Date:  2011-06

3.  Moderating Benzodiazepine Use in the Elderly: Curbing physicians' prescribing practices.

Authors:  P G Huston
Journal:  Can Fam Physician       Date:  1992-10       Impact factor: 3.275

4.  Longitudinal trends in prescribing for elderly patients: two surveys four years apart.

Authors:  R H Rumble; K Morgan
Journal:  Br J Gen Pract       Date:  1994-12       Impact factor: 5.386

5.  Correlates and prevalence of benzodiazepine use in community-dwelling elderly.

Authors:  P P Gleason; R Schulz; N L Smith; J T Newsom; P D Kroboth; F J Kroboth; B M Psaty
Journal:  J Gen Intern Med       Date:  1998-04       Impact factor: 5.128

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.